secwatch.observer — SEC 8-K summary
======================================

Issuer:     Invivyd, Inc. (IVVD)
CIK:        0001832038
Form:       8-K
Filed at:   2024-05-09T23:59:59+00:00
Accession:  0001193125-24-135260
Event type: earnings
Sentiment:  neutral
Materiality: 0.85
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Invivyd Q1 net loss $43.5M ($0.38/sh); launches PEMGARDA, guides 2024 rev $150-200M
--------------------------------------------------------------------------------

- Launched PEMGARDA (pemivibart) for COVID-19 PrEP in immunocompromised; received CMS HCPCS Q and M codes.
- Cash $189.4M at Q1 end; expects ≥$75M year-end cash on $150-200M net product revenue.
- Net loss $43.5M vs $35.3M YoY; R&D $31.2M, SG&A $14.9M.
- Plans to submit EUA for pemivibart as COVID-19 treatment in immunocompromised via rapid immunobridging.
- Advancing VYD2311 mAb candidate optimized against BA.2.86/JN.1 lineages.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1832038/000119312524135260/0001193125-24-135260-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1832038/000119312524135260/d838072d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-135260

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer